在缺铁性贫血中与铁糖相比,铁性脱脂糖:随机对照试验的元分析
Lokman H Tanriverdi1, Ahmet Sarici2, Feyzullah Aksan3
1Department of Medical Pharmacology, Faculty of Medicine, İnönü University, Malatya 44100, Türkiye.
Journal of clinical medicine
|March 14, 2026
概括
铁脱脂糖 (FDM) 和铁糖 (IS) 在治疗缺铁性贫血 (IDA) 中表现出类似的疗效和安全性. 这次系统性审查发现,两种铁疗法之间的血红蛋白水平或过敏反应没有显著差异.
科学领域:
- 血液学 血液学 血液学
- 药理学 药理学是指药理学的学科.
- 临床医学 临床医学
背景情况:
- 在治疗缺铁性贫血 (IDA) 方面,存在相互矛盾的证据,比较铁性脱脂糖 (FDM) 与铁糖 (IS) 的疗效和安全性.
- 需要进行系统评估,以澄清这两种静脉注射铁配方的治疗结果.
研究的目的:
- 在被诊断患有缺铁性贫血 (IDA) 的患者中,系统地评估和比较铁性脱脂糖 (FDM) 与铁糖 (IS) 的疗效和安全性.
主要方法:
- 在主要数据库 (Ovid MEDLINE,Web of Science,Pubmed,Cochrane Central) 进行了全面的文献搜索,寻找相关的随机对照试验 (RCT).
- 使用逆变量随机效应模型进行了元分析,以评估初级疗效 (第4周的血红蛋白变化) 和安全结果 (严重/严重的过敏反应).
主要成果:
- 包括5个RCT,涉及3470名患有一般IDA,非透析CKD或血液透析的患者.
- 关于第四周血红蛋白变化FDM与IS的证据非常不确定 (MD 0.09 g/dL,95% CI -0.33至0.52).
- 同样,严重/严重的过敏反应 (RR 0.83,95% CI 0.25至2.68) 和过敏反应 (RR 0.38,95% CI 0.08至1.72) 的证据非常不确定.
结论:
- 与铁糖 (IS) 相比,铁脱醇 (FDM) 对治疗缺铁性贫血 (IDA) 的治疗结果几乎没有显著影响.
- 现有的证据表明,FDM和IS之间在IDA管理中具有可比的有效性和安全性.
相关概念视频
Glucose Transporters
28.0K
Glucose transporters facilitate the transport of glucose across the cell membrane. In addition to glucose, some glucose transporters can also aid the movement of other hexoses such as fructose, mannose, and galactose.
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
28.0K
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
746
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
746
Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents
1.9K
In the intricate landscape of the gastric lumen, excessive acid secretion disrupts the natural defense mechanisms, weakening the mucus-bicarbonate barrier. This vulnerability allows pepsin to infiltrate epithelial cells, digesting mucosal proteins and triggering erosion, leading to ulcer formation.
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
1.9K
Precipitation and Co-precipitation
5.4K
Precipitation and coprecipitation methods can be used to separate a mixture of ions in a solution. In qualitative inorganic analysis, ions that form sparingly soluble precipitates with the same reagent are separated based on the differences in solubility products. For example, consider the separation of Cu(II) and Fe(II) ions by precipitation as insoluble sulfides. First, copper(II) sulfide is precipitated by the addition of acidic H2S, where the dissociation of H2S is suppressed. Adding H2S...
5.4K
The Early Endosome: Endocytosis of Transferrin
5.1K
Essential proteins such as insulin or low-density lipoprotein (LDL) and micronutrients such as iron enter a eukaryotic cell through receptor-mediated endocytosis. Subsequently, the early endosomes fuse with the vesicles containing such receptor-ligand complexes and play a vital role in sorting the incoming ligands and receptors. While the ligands are either degraded inside the vesicle or released into the cytosol, their receptors are returned to the plasma membrane for further rounds of...
5.1K


